Cardiac amyloidosis: when to suspect and how to confirm

Area of Science:

• Cardiology
• Medical Diagnostics
• Genetics

Background:

• Cardiac amyloidosis (CA) diagnosis is challenging due to phenotypic heterogeneity, multiorgan involvement, and limited medical awareness.
• Delayed diagnosis of CA can negatively impact patient outcomes by omitting or delaying life-saving treatments.
• Suspicion of CA should be raised with specific red flags and increased left ventricular wall thickness.

Purpose of the Study:

• To outline the diagnostic challenges and strategies for cardiac amyloidosis.
• To emphasize the importance of amyloid typing for guiding treatment decisions.
• To highlight key diagnostic steps including red flags, imaging, and laboratory tests.

Main Methods:

• The abstract discusses the diagnostic process for CA, emphasizing clinical suspicion based on red flags and increased left ventricular wall thickness.
• Diagnostic workup includes amyloid typing to differentiate between light chain (AL) and transthyretin cardiac amyloidosis (ATTR-CA).
• Key diagnostic tools mentioned are bone tracer uptake, monoclonal protein detection, tissue biopsy (if needed), and genetic testing for TTR mutations in ATTR-CA.

Main Results:

• Accurate diagnosis requires differentiating between AL and ATTR-CA, which is critical for specific treatment selection.
• Prompt initiation of the diagnostic process involves assessing bone tracer uptake and searching for monoclonal proteins.
• Tissue biopsy may be necessary when monoclonal protein is detected or bone tracer uptake is equivocal; genetic testing is essential for all ATTR-CA patients.

Conclusions:

• Effective diagnosis and management of cardiac amyloidosis necessitate addressing its complexity and improving medical awareness.
• Amyloid typing is paramount for tailoring treatment strategies, distinguishing between AL and ATTR-CA forms.
• A systematic diagnostic approach, incorporating red flags, imaging, and genetic testing, is vital for optimal patient care.